Cartesian Therapeutics Inc. (RNAC) — Cash Flow Reinvestment Rate
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Reinvestment Rate of 0.91x as of September 2024, reinvesting $12.40 Million (capex $6.20 Million plus investments $-6.20 Million) from operating cash flow of $13.69 Million. See how much free cash does Cartesian Therapeutics Inc. generate to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cartesian Therapeutics Inc. Cash Flow Reinvestment Rate (2020–2020)
Historical reinvestment intensity for Cartesian Therapeutics Inc. across 1 annual periods. For the full cash flow conversion analysis, see Cartesian Therapeutics Inc. cash flow conversion.
Annual Cash Flow Reinvestment Rate for Cartesian Therapeutics Inc. (2020–2020)
Year-by-year capital reinvestment analysis for Cartesian Therapeutics Inc.. See Cartesian Therapeutics Inc. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 0.04x | $1.56 Million | $34.88 Million | $815.00K | — |